Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Spero Therapeutics

Explore full profile

Multi-Asset, clinical-stage biopharmaceutical company focused on multidrug-resistant bacterial infections

Cambridge, United StatesFounded 2013Biotech & Life Sciences
Valuation $14M Market cap · Aug/2026
Revenue $60M Latest reported FY
EBITDA $8.0M Latest reported FY

At a glance

Status
Listed
Founded
2013
Headquarters
Cambridge, United States
Listing
IPO 2017
Sector
Biotech & Life Sciences
Power Law
Colt$25–100M revenue

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

Series A5 investors entered at this stage

  • Partners Innovation Fund
  • Lundbeckfonden Ventures
  • SR One
  • The Kraft Group
  • Lundbeckfonden

Series B and later6 investors entered at this stage

  • Massachusetts General Hospital
  • Rock Springs Capital
  • Osage University Partners
  • GV
  • RA Capital Management
  • Harvard Medical School
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia 4 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Spero Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Spero Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.